Allergan Plc (NYSE:AGN) Investigates Kybella As Remedy For Bra-Line Fat

Allergan Plc (NYSE:AGN) is seeking alternative ways of increasing sales for its facial injectable kybella and the elimination of bra-line fat is one of the segments of the study.

Story continues below

The pharmaceutical company is launching clinical trials of Kybella as a remedy for bra-line fat and the fat located around the knees and ankles. Ronny Gal, an analyst at Bernstein recently wrote to customers about the company’s ongoing plans. The firm hopes that the new endeavors will help bring on board some new indications that will add to the drug’s approval for the elimination of chin fat. Kybella is one of the most lucrative drugs for Allergan.

The company recently sold its generics division to Teva Pharmaceutical Industries Ltd (NYSE:TEVA). Prior to the sale of the generic unit, Allergan’s merger plans with Pfizer Inc. (NYSE:PFE) were rejected by the US Treasury. The company’s CEO Brent Saunders stated that the strategy that Allergan is pursuing is “owning the face” and that the firm expects the drug to give it leeway to the lower face. Bill Meury who is the company’s commercial officer revealed the details to the company’s investors during Allergan’s second quarter earnings call.

Allergan believes that the new strategy will open up opportunities for new consumer markets, particularly for male customers. During the earnings call, Meury stated that everything has so far been streamlined and is going as planned. The company has successfully managed to kick off the first phase of Kybella including the training of more than 90% of the major dispatchers in the US.

Allergan is also working towards the introduction of physical education to the major injectors. Meury also stated that the firm is also working towards generating more demand from customers and also spreading awareness about Kybella. Allergan will use its DTC campaign which it will launch this month to boost both. The company also hopes that the efforts will have a positive impact on its stock performance.

An ad to help with our costs